Drug intelligence / Profile preview

OC101 + OC111

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules

Overview

OC101 + OC111 is an investigational combination therapy being developed by Oncocross for the treatment of non-alcoholic steatohepatitis (NASH). Discovered via the RAPTOR AI™ platform, this combination is designed to target the complex, multi-gene expression signatures associated with NASH rather than focusing on a single protein target. One component, OC101, is an incrementally modified drug also being evaluated as a monotherapy for liver cirrhosis. The combination aims to address both the metabolic and fibrotic components of NASH and is currently in the IND-enabling stage of preclinical development.

Beyond the preview

Go deeper on OC101 + OC111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC101 + OC111.

Explore the full profile